Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Business Wire
– Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance – – First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with anemia due to chronic kidney disease – – Multiple vadadustat phase 3 readouts expected over next 18 months – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “2018 was a transformational year for Akebia,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We successfully executed a number of strategic initiatives to advan
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management [Seeking Alpha]Seeking Alpha
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?PR Newswire
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 4/16/24 - Form 8-K
- 3/28/24 - Form 8-K
- 3/15/24 - Form 8-K
- AKBA's page on the SEC website